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Abstract
Upon viral infection, the mitochondrial antiviral signaling (MAVS)-IKKb pathway is activated to restrict viral replication.
Manipulation of immune signaling events by pathogens has been an outstanding theme of host-pathogen interaction. Here
we report that the loss of MAVS or IKKb impaired the lytic replication of gamma-herpesvirus 68 (cHV68), a model
herpesvirus for human Kaposi’s sarcoma-associated herpesvirus and Epstein-Barr virus. cHV68 infection activated IKKb in a
MAVS-dependent manner; however, IKKb phosphorylated and promoted the transcriptional activation of the cHV68
replication and transcription activator (RTA). Mutational analyses identified IKKb phosphorylation sites, through which RTA-
mediated transcription was increased by IKKb, within the transactivation domain of RTA. Moreover, the lytic replication of
recombinant cHV68 carrying mutations within the IKKb phosphorylation sites was greatly impaired. These findings support
the conclusion that cHV68 hijacks the antiviral MAVS-IKKb pathway to promote viral transcription and lytic infection,
representing an example whereby viral replication is coupled to host immune activation.
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Introduction
Host cells activate innate immune signaling pathways to defend
against invading pathogens. Pattern recognition receptors, includ-
ing Toll-like receptors and cytosolic sensors (such as NOD-like
receptors and RIG-I-like receptors), recognize pathogen-associat-
ed structural components and initiate signal transduction that
leads to the biosynthesis and secretion of pro-inflammatory
cytokines and interferons, thereby mounting a potent host immune
response [1,2]. To survive within an infected host, viruses have
evolved intricate strategies to counteract host immune responses.
Herpesviruses and poxviruses have large genomes and therefore
have the capacity to encode numerous proteins that modulate host
immune responses.
Mitochonrial antiviral signaling (MAVS, also known as IPS-1,
VISA, and CARDIF) protein serves as an adaptor to activate both
the NFkB and interferon regulatory factor (IRF) pathways
[3,4,5,6]. MAVS relays signals from RIG-I and MDA-5, cytosolic
sensors that recognize viral dsRNA or ssRNA bearing 59-
triphosphate [7,8], to the IKKa/b/c and TBK-1/IKKe (also
known as IKKi) kinase complexes [4,6]. IKKa/b, together with
the scaffold protein IKKc, phosphorylates the inhibitor of NFkB
(IkB) and promotes its subsequent ubiquitination and degradation
by the proteasome, thereby unleashing NFkB that translocates
into the nucleus to activate gene expression of pro-inflammatory
cytokines [9,10]. By contrast, TBK-1 and IKKe directly
phosphorylate a serine/threonine-rich sequence within the
carboxyl termini of IRF3 and IRF7, leading to the dimerization
and nuclear translocation of these transcription factors [11,12].
Together with NFkB and c-Jun/ATF-2, IRF3 and IRF7 bind to
the interferon (IFN)-b enhancer and initiate the transcription of
IFN-b [13,14]. Ultimately, these signaling events promote
cytokine and interferon production, establishing an antiviral state
in infected cells. Although it is not clear how MAVS activates these
immune kinases, recent findings have established the vital roles of
MAVS in host antiviral innate immunity [15]. Interestingly, the
mitochondrial localization of MAVS is critical for its ability to
activate downstream signaling events. As such, various RNA
viruses, exemplified by human hepatitis C virus (HCV), encode
proteases that cleave MAVS from the outer membrane of the
mitochondrion, thereby disarming MAVS-dependent signaling
cascades and the host antiviral innate immunity [6,16,17,18].
Murine gamma-herpesvirus 68 (cHV68 or MHV-68) is closely
related to human Kaposi’s sarcoma-associated herpesvirus (KSHV)
and Epstein-Barr virus (EBV) [19]. KSHV and EBV are
lymphotropic DNA viruses that are causally linked to malignancies
of lymphoid or endothelial/epithelial origin, including lymphoma,
nasopharyngeal carcinoma, and Kaposi’s sarcoma [20,21]. Persist-
ing within host immune cells, KSHV and EBV are known to evade,
manipulate, and exploit host immune pathways [22,23]. Emerging
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responses for their infection [24,25,26]. However, it is not known
how human KSHV and EBV manipulate innate immune pathways
in vivo. Such investigations are greatly hampered by the lack of
permissive cell lines and animal models for both KSHV and EBV.
By contrast, cHV68 infection in laboratory mice leads to a robust
acute infection in the lung and a long-term latent infection in the
spleen. For murine cHV68 and human KSHV, the replication and
transcription activator (RTA, encoded by ORF50) is necessary and
sufficient to initiate lytic replication from latently-infected cells,
supporting the notion that RTA integrates diverse signaling
pathways to initiate lytic replication [27,28,29]. Using cHV68 as
a surrogate for human KSHV and EBV, we have unexpectedly
discovered that cHV68 activated IKKb to phosphorylate RTA and
promote RTA transcriptional activation, thereby increasing viral
gene transcription and lytic replication. As such, RTA phosphor-
ylation by IKKb couples cHV68 gene expression and lytic
replication to host innate immune activation, representing the first
example whereby a virus hijacks the antiviral MAVS-IKKb
pathway to promote its lytic replication.
Results
MAVS is Necessary for Efficient cHV68 Lytic Replication
To investigate the roles of MAVS in cHV68 infection, wild-type
(MAVS
+/+), heterozygous (MAVS
+/2), and knockout (MAVS
2/2)
mice were intranasally (i.n.) infected with 40 plaque-forming unit
(PFU) cHV68. cHV68 acute infection in the lung was measured
by plaque assays at 4, 7, 10, 13, and 16 days post-infection (d.p.i.).
In MAVS
+/+ mice, cHV68 titers peaked at 7 d.p.i. with
approximately 500 PFU/lung and declined to 100 PFU/lung at
10 d.p.i. Viral load was undetectable by 13 d.p.i., indicating that
cHV68 acute infection in the lung had been cleared (Figure 1A).
Similar viral loads in the lungs of heterozygous mice (MAVS
+/2)
were observed (data not shown). Surprisingly, although viral loads
at 7 d.p.i. in the lungs of MAVS
2/2 mice were comparable to
those in the lungs of MAVS
+/+ mice, cHV68 was nearly
undetectable at 10 d.p.i. (Figure 1A). By contrast, cHV68 latent
infection as characterized by viral genome frequency, persistent
lytic replication, and reactivation was similar in splenocytes of
MAVS
+/+ and MAVS
2/2 mice at 16 and 45 d.p.i. (Figure S1).
These observations suggest that MAVS plays a specific role(s) in
cHV68 acute infection.
To determine whether cHV68 infection altered MAVS
expression, we infected BL/6 mice intranasally with a high dose
(1610
5 PFU) of cHV68, presumably permitting synchronized and
maximal infection of lung epithelial cells. MAVS mRNA levels
were determined by quantitative real-time PCR (qRT-PCR). The
levels of MAVS mRNA were transiently increased at 2.5 and 5
d.p.i. in the lung and spleen, respectively (Figure S2A).
Interestingly, the up-regulation of MAVS mRNA preceded that
of viral RTA mRNA (Figure S2A and S2B), and that higher viral
RTA mRNA levels tightly correlated with higher MAVS mRNA
levels at 2.5 and 5 d.p.i., when MAVS mRNA levels peaked in the
lung and spleen (Figure S2C). Together with the reduced viral
load in the lungs of MAVS
2/2 mice (Figure 1A), these results
suggest that MAVS is necessary for efficient lytic replication in
mice and that the transiently induced MAVS expression by
cHV68 infection may facilitate viral lytic replication in vivo.
To investigate the roles of MAVS in cHV68 infection, we then
assessed the effects of MAVS-deficiency on cHV68 lytic
replication ex vivo. Mouse embryonic fibroblasts (MEFs) were
infected with a GFP-marked recombinant cHV68 (cHV68 K3/
GFP) and viral replication was examined by fluorescence
microscopy and plaque assays. Surprisingly, cHV68 displayed
delayed replication kinetics in MAVS
2/2 MEFs compared to
MAVS
+/+ MEFs at multiplicities of infection (MOI) of 0.01 and
0.1 (Figure 1B, 1C and S3). To quantitatively determine the effect
of MAVS on cHV68 lytic infection, we examined cHV68 lytic
replication in MAVS
+/+ and MAVS
2/2 MEFs by plaque assays.
In fact, cHV68 formed approximately four-fold more plaques in
MAVS
+/+ MEFs than those in MAVS
2/2 MEFs, indicative of
reduced initiation of lytic replication in MAVS-deficient MEFs
(Figure 1D, S4A, and S4B). Interestingly, the plaque size of
cHV68 was equivalent in MAVS
+/+ and MAVS
2/2 MEFs
(Figure S4C and S4D). To test whether MAVS
2/2 MEFs are
defective in supporting viral lytic replication in general, we
examined the lytic replication of vesicular stomatitis virus (VSV), a
prototype RNA virus, with a plaque assay. Consistent with an
antiviral activity of MAVS against RNA viruses, VSV formed 10-
fold more plaques in MAVS
2/2 MEFs than those in MAVS
+/+
MEFs (Figure 1D). The diminished lytic replication of cHV68 in
MAVS-deficient MEFs is consistent with the reduced acute
infection observed in the lung. To test whether exogenously
expressed MAVS is able to restore cHV68 lytic replication, we
generated lentivirus in 293T cells and MEFs stably expressing
human MAVS (hMAVS) was established with puromycin selection
(Figure 1E). As shown in Figure 1F and 1G, exogenous hMAVS
restored cHV68 lytic replication by a plaque assay and multi-step
growth curves. Nevertheless, these results together support the
conclusion that MAVS is necessary for efficient cHV68 lytic
replication in vivo and ex vivo.
The IKKb/c Complex is an Effector Downstream of MAVS
in cHV68 Lytic Replication
Two known pathways, the IKKa/b/c-NFkB and TBK-1/
IKKe-IRF3/7 pathway, have been characterized downstream of
MAVS (Figure 2A) [3,4]. We therefore used MEFs deficient in key
components of aforementioned pathways to identify downstream
effectors of MAVS that are critical for cHV68 lytic infection.
Plaque assays and multi-step growth curves of cHV68 lytic
infection showed that deficiency in TRAF6, IKKc, and IKKb, but
not deficiency in the closely related IKKa, recapitulated
phenotypes of MAVS deficiency (Figure 2B and 2C). Notably,
TRAF6 is necessary for MAVS to activate IKKb that requires
IKKc, a scaffold protein for both IKKa and IKKb [5]. By
contrast, deficiency in type I IFN receptor (IFNAR) and double
Author Summary
Innate immunity represents the first line of defense against
pathogen infection. Recent studies uncovered an array of
sensors that detect pathogen-associated molecular pat-
terns and induce antiviral cytokine production via two
closely related kinase complexes, i.e., the IKKa/b/c and
TBK-1/IKKe. To counteract host immune defense, herpes-
viruses have evolved diverse strategies to evade, manip-
ulate, and exploit host immune responses. Here we report
that infection by murine gamma-herpesvirus 68 (cHV68), a
model gamma-herpesvirus for human Kaposi’s sarcoma-
associated herpesvirus and Epstein-Barr virus, activated the
IKKb kinase and IKKb was usurped to promote viral
transcriptional activation. As such, uncoupling IKKb from
transcriptional activation by biochemical and genetic
approaches impaired cHV68 lytic replication. Our study
represents an example whereby viral lytic replication is
coupled to host innate immune activation and sheds light
on herpesvirus exploitation of immune responses.
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PLoS Pathogens | www.plospathogens.org 2 July 2010 | Volume 6 | Issue 7 | e1001001Figure 1. MAVS deficiency reduces cHV68 lytic replication. MAVS wild-type (MAVS
+/+) or knockout (MAVS
2/2) mice were intranasally (i.n.)
infected with 40 PFU cHV68. The lungs were harvested at 4, 7, 10, 13, and 16 days post-infection (d.p.i.) and viral titer was determined by a plaque
assay. (B) Mouse embryonic fibroblasts (MEFs) were infected with a GFP-marked cHV68 K3/GFP at multiplicities of infection (MOI) of 0.01. Viral
replication in MAVS
+/+ and MAVS
2/2 MEFs were photographed. (C) MEFs were infected with cHV68 K3/GFP as in (B) and viral titers were determined
by a plaque assay. Data represent three independent experiments and error bars denote standard error of the mean (SEM). (D) MAVS
+/+ and MAVS
2/2
MEFs were infected with 120 PFU cHV68 K3/GFP or 5 PFU vesicular stomatitis virus (VSV), and plaques were counted. Data represent the mean 6 SEM
of three independent experiments. (E to G) MAVS
2/2 MEFs were respectively infected with control lentivirus (Vec) or lentivirus containing the Flag-
tagged human MAVS (MAVS), and selected with puromycin. (E) MAVS expression was confirmed by immunoprecipitation and immunoblot with anti-
Flag antibody. (F) cHV68 plaque assays were performed as in (D). (G) Reconstituted MAVS
2/2 MEFs as indicated were infected with cHV68 K3/GFP
(MOI=0.01), and viral multi-step growth was determined by a plaque assay. Statistical significance in (A), (D), and (F): *, P,0.05; **, P,0.02;
***, P,0.005.
doi:10.1371/journal.ppat.1001001.g001
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PLoS Pathogens | www.plospathogens.org 3 July 2010 | Volume 6 | Issue 7 | e1001001Figure2. TheMAVS-IKKb pathway is necessaryfor efficientcHV68 lyticreplication ex vivo. (A)Two knownpathways,theIKKa/b/c-NFkB and
TBK-1/IKKe-IRF pathways, downstream of MAVS. (B) The initiation of cHV68 lytic replication in wild-type (WT) MEFs and MAVS
2/2, IKKa
2/2, IKKb
2/2,
IKKc
2/2, TRAF6
2/2, IFNAR
2/2, and IRF3
2/2IRF7
2/2 (double knockout) MEFs was assessed by a plaque assay. Data represent the mean 6 SEM of three
independent experiments. (C) Multi-step growth properties of cHV68 (MOI=0.01) in wild-type MEFs and IKKb
2/2, IKKc
2/2, and IKKa
2/2 MEFs were
examined by plaque assays. Data represents three independent experiments. (D to F) Wild-type, MAVS
2/2,a n dI K K b
2/2 MEFs were respectively
infected with control lentivirus (Vec) or lentivirus containing the Flag-tagged IKKb (IKKb), and selected with puromycin. (D) IKKb expression was
confirmed by immunoprecipitation and immunoblot with anti-Flag antibody (top). cHV68 plaque assays were performed as in (B). (E)
Reconstituted MEFs of indicated genotypes were used for cHV68 plaque assays as in (B) with increasing doses of cHV68. Data represent the mean
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PLoS Pathogens | www.plospathogens.org 4 July 2010 | Volume 6 | Issue 7 | e1001001deficiency in IRF3 and IRF7 had no discernable effect on the
plaque numbers of cHV68 in MEFs, indicating that the IRF-IFN
signaling pathway is not critical for the initiation of cHV68 lytic
replication (Figure 2B). Furthermore, the exogenous IKKb
expression reconstituted by lentivirus restored the lytic replication
of cHV68 as determined by a plaque assay and multi-step growth
curves (Figure 2D, 2E, and 2F). Interestingly, the expression of
IKKb in MAVS
2/2 did not increase cHV68 lytic replication by a
plaque assay (Figure 2E), suggesting that the MAVS-dependent
activation of IKKb, rather than the absolute expression level of
IKKb, is crucial for efficient cHV68 lytic replication. Additionally,
exogenous IKKb did not increase cHV68 plaque numbers in
MAVS
+/+ MEFs (Figure 2E), implying that endogenous IKKb is
sufficient to support efficient cHV68 lytic replication. Of note,
lentivirus infection reduces the difference of cHV68 plaque
forming capacity in wild-type MEFs and in MEFs deficient in
MAVS and IKKb (Figure 1F and 2D). Collectively, these data
indicate that the MAVS-dependent IKKb activation is critical for
efficient cHV68 lytic replication.
To assess whether the kinase activity of IKKb is important for
cHV68 lytic infection, we performed plaque assays with or without
the specific IKKb inhibitor, Bay11-7082 (Bay11). This experiment
revealed that Bay11 reduced the plaque number of cHV68 in a
dose-dependent manner (Figure 3A). Whereas treatment with
1 mM of Bay11 at 0.5 h before infection reduced cHV68 plaque
number by 52%, the same treatment at 7 h post-infection (h.p.i.)
reduced the plaque number by 29%, emphasizing the important
roles of IKKb during early cHV68 infection (Figure 3A). We
further examined IKKb activity by an in vitro kinase assay with
IKKb precipitated from MAVS
+/+ and MAVS
2/2 MEFs infected
with cHV68. The IKKb kinase activity was transiently and
moderately increased in MAVS
+/+ MEFs, however, it was
drastically diminished in MAVS
2/2 MEFs after cHV68 infection
(Figure 3B). The activation of IKKb was further supported by the
rapid degradation of IkBa concurrent to IKKb activation by
cHV68 infection in MAVS
+/+ MEFs, but not in MAVS
2/2 MEFs
(Figure 3C). To test whether UV-inactivated virus is able to trigger
IKKb activation, we examined the levels of IKKb kinase activity
and IkBa in MAVS
+/+ MEFs by in vitro kinase and immunoblot
assays, respectively. Interestingly, UV-inactivated cHV68 activat-
ed IKKb and reduced IkBa protein levels, although less efficiently
than live cHV68 (Figure 3D and 3E). This observation suggests
that cHV68 lytic replication is necessary to activate the MAVS-
IKKb pathway. Alternatively, UV treatment may damage or
disrupt viral structural components whose integrity is necessary to
activate the MAVS-IKKb pathway.
MAVS activation by RNA viruses is known to increase the
expression of pro-inflammatory cytokines and interferons. Howev-
er, cHV68 appears to be a poor inducer for these antiviral
molecules, suggesting that cHV68 evades signaling events down-
streamoftheMAVSadaptor.Indeed,cHV68 infectionfailed toup-
regulate the expression of IFN-b (Figure S5A). In agreement with
this observation, cHV68 RTA, similar to KSHV RTA [30], is
sufficienttoreduceIRF3expression(FigureS5B).Meanwhile,itwas
previously shown that cHV68 infection did not significantly activate
NFkB duringearly infection[31],suggesting that cHV68 uncouples
NFkB activation from activated IKKb. Taken together, these
results support the conclusion that cHV68 infection selectively
activates IKKb to promote viral lytic replication.
The MAVS-IKKb Pathway is Implicated in cHV68
Transcriptional Activation
To discern the molecular mechanisms underlying the require-
ment of the MAVS-IKKb pathway in cHV68 lytic infection, levels
of cHV68 genomic DNA and mRNA were assessed by PCR or
reverse transcription followed by real-time PCR analyses, respec-
tively. At a low MOI (0.01), analyses by PCR (Figure 4A) and real-
time PCR (Figure 4B) revealed comparable levels of viral genomes
in MAVS
+/+ and MAVS
2/2 MEFs early after de novo infection,
suggesting comparable viral entry into MAVS
+/+ and MAVS
2/2
MEFs. Interestingly, levels of viral mRNA transcripts representing
immediate early (RTA, ORF73, and ORF57) and early (ORF60
and ORF9) gene products in MAVS
+/+ MEFs were higher than
those in MAVS
2/2 MEFs as determined by reverse-transcriptase
PCR (Figure 4C). Real-time PCR analyses with cDNA showed
approximately 4- to 16-fold higher levels of cHV68 mRNA
transcripts in MAVS
+/+ MEFs compared to those in MAVS
2/2
MEFs at 2 and 3 d.p.i. (Figure 4D). It has been shown that TRAF6
is necessary for MAVS to activate IKKb [5] and exogenous TRAF6
is sufficient to activate IKKb. To further examine the effects of the
MAVS-IKKb pathway on levels of cHV68 mRNA transcripts, a
bacterial artificial chromosome (BAC) containing the cHV68
genome and a plasmid expressing TRAF6 were transfected into
293T cells. The effects of exogenous TRAF6 (that activates IKKb)
on viral transcription were determined by reverse transcription and
real-time PCR. At 28 h post-transfection, a time point when
immediate earlyandearlygenesaretranscribed,exogenousTRAF6
efficiently increased the mRNA levels of cHV68 RTA, ORF57,
ORF60, and ORF73, without discernable effect on levels of viral
genomic DNA (Figure 4E and 4F). These results, obtained under
conditions of loss of function (MAVS
2/2 MEFs) and gain of
function (TRAF6 expression), indicate that the activated IKKb
increases the levels of cHV68 mRNA transcripts.
IKKb Phosphorylates cHV68 RTA and Promotes cHV68
Transcription
MAVS is an adaptor that activates IKKb and the MAVS-
dependent IKKb increases cHV68 mRNA levels. We thus
postulated that MAVS influences cHV68 transcription via its
downstream IKKb on RTA, because RTA, the master transcrip-
tion activator, is critical for cHV68 lytic replication. To test this
hypothesis, we examined whether IKKb phosphorylates cHV68
RTA. IKKb was purified from 293T cells and bacterial GST
fusion proteins containing the RTA internal region (RTA-M, aa
335–466) or the RTA C-terminal transactivation domain (RTA-C,
aa 457–583) were purified from E.coli (Figure 5A). In the presence
of [
32P]cATP, IKKb efficiently transferred the phosphate group to
GST-RTA-C. By contrast, GST was not phosphorylated and
GST-RTA-M was weakly phosphorylated by IKKb. Furthermore,
the kinase domain deletion variant of IKKb (IKKbDKD) failed to
phosphorylate GST-RTA-C and GST-RTA-M (Figure 5A), and
IKKa had only residual kinase activity toward RTA-C (Figure S6).
To confirm the MAVS- and IKKb-dependent phosphorylation of
RTA, RTA phosphorylation in cHV68-infected cells was analyzed
by autoradiography and immunoblot. We found that MAVS- and
IKKb deficiency reduced RTA phosphorylation by 50% and
85%, respectively, while reconstituted IKKb expression restored
RTA phosphorylation to that of RTA in MAVS
+/+ MEFs
6 SEM of three independent experiments. (F) Reconstituted IKKb
2/2 MEFs as indicated were infected with cHV68 K3/GFP (MOI=0.01), and viral
multi-step growth was determined by a plaque assay. Statistical significance (P-value) in (B), (D), and (E) was calculated with two-tailed unpaired
Student’s t-test: *, P,0.05; **, P,0.02; ***, P,0.005.
doi:10.1371/journal.ppat.1001001.g002
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PLoS Pathogens | www.plospathogens.org 5 July 2010 | Volume 6 | Issue 7 | e1001001Figure 3. cHV68 infection activates IKKb in a MAVS-dependent manner. (A) Wild-type MEFs were treated with the IKKb inhibitor, Bay11-
7082, for 30 min at 0.5 h before infection or 7 h post-infection (h.p.i.) with cHV68. Cells were washed with medium and incubated for plaque
formation. Plaques formed at 6 d.p.i. were counted. Data represent the mean 6 SEM. (B) MEFs were infected with cHV68 (MOI=10) and whole cell
lysates of MEFs at indicated time points after cHV68 infection were precipitated with anti-IKKb antibody. One half of IKKb was used for an in vitro
kinase assay with GST-IkBNT (amino terminal 50 amino acids of IkBa) (top) or analyzed by immunoblot (middle). Relative intensity of phosphorylated
GST-IkBNT was normalized to IKKb protein (bottom). (C) cHV68 infection was carried out as in (B) and whole cell lysates were analyzed by
immunoblot with anti-IkBa (top) and b-actin (bottom). (D and E) Equal amount of live (MOI=10) or UV-inactivated (UV) cHV68 was used to infect
wild-type MEFs. The IKKb kinase activity was assessed as in (B) and whole cell lysates were analyzed by immunoblot as in (C) for IkBa and b-actin.
Graphs at the bottom show normalized IKKb kinase activity (D) and IkBa protein (E).
doi:10.1371/journal.ppat.1001001.g003
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PLoS Pathogens | www.plospathogens.org 6 July 2010 | Volume 6 | Issue 7 | e1001001Figure 4. The MAVS-IKKb pathway is important for cHV68 mRNA production. (A and B) MAVS
+/+ and MAVS
2/2 MEFs were infected with
cHV68 (MOI=0.01) and cells were harvested at two hours post-infection. Total DNA was extracted and viral genomes were analyzed by PCR and
agarose gel electrophoresis (A) or quantitative real-time PCR (qRT-PCR) (B). (C and D) MEFs were infected with cHV68 as in (A). Total RNA was
extracted and levels of cHV68 mRNA transcripts were examined by reverse transcription and PCR (C) or qRT-PCR (D) using primers specific for viral
genes as indicated. I.E., immediate early; E, early. (E and F) 293T cells were transfected with the cHV68 BAC and a plasmid containing TRAF6. At 28 h
post-transfection, levels of the cHV68 genome were determined by qRT-PCR (E) and levels of various cHV68 gene transcripts as indicated were
determined by reverse transcription and qRT-PCR analyses (F). Data represent the mean 6 SEM.
doi:10.1371/journal.ppat.1001001.g004
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PLoS Pathogens | www.plospathogens.org 7 July 2010 | Volume 6 | Issue 7 | e1001001Figure 5. IKKb phosphorylates and potentiates the transcription activity of cHV68 RTA. (A) IKKb or IKKbDKD purified from 293T cells (left)
were incubated with [
32P]cATP and bacterial GST fusion proteins containing RTA fragments (middle), and examined by autoradiography (right). (B)
MEFs of indicated genotype were infected with cHV68 (MOI=2) for 4 h, labeled with [
32P]-orthophosphoric acid for 8 h. Whole cell lysates were
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transcription regulation, luciferase reporter assays were carried out
with plasmids containing RTA-responsive promoters of RTA,
ORF57, and M3. As shown in Figure 5C, the transcription activity
of RTA on all three promoters was significantly increased by
exogenous TRAF6 and IKKb, but not by the kinase dead variant
IKKbDKD, supporting the notion that IKKb promotes RTA
transcription activation via phosphorylation. When expressed to
similar levels of IKKb, IKKbDKD had no significant effect on
RTA transcriptional activation (Figure S7). Given that RTA is a
substrate for IKKb, we sought to examine whether RTA can
physically associate with the IKKa/b/c complex. However, we
were unable to detect interaction between RTA and any of the
three subunits of IKKa/b/c by co-immunoprecipitation (data not
shown), suggesting that the RTA interaction with the IKKa/b/c
complex is transient or mediated via additional cellular proteins.
To identify IKKb phosphorylation sites, series of truncations
from the C-terminus of RTA were constructed and purified as
GST fusion proteins for in vitro kinase assays with IKKb. These
experiments demonstrated that the IKKb phosphorylation sites
were located within the region containing residues 540 through
567 (Figure S8). Given that IKKb is a serine/threonine kinase,
clusters of various serine/threonine residues were changed to
alanines and RTA phosphorylation was assessed similarly. Two
clusters of mutations, replacement of S550T552S556 (STS/A) and
T561T562S564 (TTS/A) by alanines, reduced the phosphorylation
levels of RTA-C by approximately 72% and 45%, respectively
(Figure 5D and S8). These results indicate that the STS and TTS
sequences represent two major IKKb phosphorylation sites within
the transactivation domain of RTA.
To further examine the roles of IKKb phosphorylation in
regulating RTA transcription activity, reporter assays with
plasmids containing wild-type RTA, the STS/A and TTS/A
variants were carried out with exogenously expressed IKKb. The
STS/A and TTS/A variants had lower basal activity to activate
promoters of RTA, ORF57, and M3. Moreover, exogenous IKKb
failed to further stimulate the transcription activities of the STS/A
and TTS/A variants to activate promoters of RTA and ORF57
(Figure 5E). Interestingly, the STS/A variant activated M3
promoter to the level of wild-type RTA with or without IKKb,
indicating that the STS site is dispensable for IKKb to promote
RTA transcriptional activity on the M3 promoter (Figure 5E). It is
noteworthy that the STS/A and TTS/A variants were expressed
at higher levels than wild-type RTA, the transcription activities of
the STS/A and TTS/A variants were approximately 50% and
20% of that of wild-type RTA, respectively, when luciferase
activity was normalized against protein levels (Figure 5F).
Collectively, these results demonstrated that IKKb promotes
RTA transcriptional activation via phosphorylation of the TTS
and STS sites within the transactivation domain.
Impaired Lytic Replication of Recombinant cHV68
Carrying Mutations within the IKKb Phosphorylation Sites
To further investigate the roles of RTA phosphorylation, we
assessed the effects of the STS/A and TTS/A mutations on
cHV68 lytic replication. Taking advantage of the cHV68-
containing BAC with a transposon insertion that inactivates
RTA (ORF50 Null) [32], a recombination-based strategy [33] was
employed to generate viruses carrying wild-type RTA (Null
Rescued, designated NR), the STS/A allele, or the TTS/A allele
(Figure 6A). Whereas we easily obtained recombinant cHV68
containing wild-type RTA (cHV68.NR) or the TTS/A allele
(cHV68.TTS/A), the STS/A variant failed to support cHV68
recombination in multiple independent experiments. This obser-
vation suggests an essential role for the phosphorylated STS
sequence in cHV68 lytic replication. To confirm the integrity of
viral genomic DNA, we performed restriction digestion with KpnI
and EcoRI, and analyzed with agarose gel electrophoresis. As
expected, the removal of the Kanamycin cassette within RTA
alleles reduced the 9-kb fragment to 7.5-kb counterpart released
by KpnI digestion (Figure 6B), and abolished an EcoRI site within
the Kanamycin cassette (Figure 6C). To assess the transcriptional
activity of RTA derived from BAC DNA, BAC DNA and the M3p
luciferase reporter plasmid were transfected into 293T cells and
RTA transcriptional activity was assessed by luciferase reporter
assay. The activity of wild-type RTA to activate M3 promoter was
approximately 6-fold higher than that of the TTS/A mutant
(Figure 6D). Using 293T cells transfected with the cHV68 BAC
containing the TTS/A allele and a plasmid expressing TRAF6, we
assessed the effects of TRAF6 (that activates IKKb)o ncHV68
gene expression. In contrast to what was observed for the cHV68
BAC containing wild-type RTA (Figure 4F), exogenous TRAF6
had marginal effects on the levels of viral mRNAs transcribed from
cHV68 BAC containing the TTS/A allele (Figure 6E). These
findings are consistent with the observation that IKKb failed to
further promote the transcription of the TTS/A variant
(Figure 5E), supporting the conclusion that the TTS residues
constitute an IKKb phosphorylation sequence by which RTA-
dependent transcription is positively regulated.
Next, we examined whether recombinant cHV68.TTS/A
recapitulates the defects of wild-type cHV68 lytic replication in
MEFs deficient in MAVS and IKKb (plaque assays and multi-step
growth curves). To assess the effects of the TTS/A mutation on
cHV68 transcription activation, we normalized viral genomes
immediately after cHV68 de novo infection of MEFs by qRT-PCR.
With equal number of viral genomes, cHV68.NR displayed
approximately 32-fold higher of RTA mRNA than recombinant
cHV68.TTS/A in MAVS
+/+ MEFs at 30 h.p.i. (Figure 7A). This
is consistent with the observation that RTA activates its own
promoter to facilitate viral lytic replication (Figure 5C and 5E).
Furthermore, multi-step growth curves (at an MOI of 0.01)
demonstrated that cHV68.TTS/A had delayed replication
kinetics and produced .3 orders of magnitude less virion progeny
in MAVS
+/+ MEFs (Figure 7B). To test whether RTA
phosphorylation and the MAVS-IKKb pathway are functionally
redundant, we examined the replication kinetics of recombinant
cHV68.NR and cHV68.TTS/A in wild-type, MAVS
2/2, and
IKKb
2/2 MEFs. Consistent with our previous observations
(Figure 1C, 2C, and S3B), cHV68.NR showed delayed lytic
replication in MAVS
2/2 and IKKb
2/2 MEFs (Figure 7B and
7C). Remarkably, cHV68.TTS/A replicated with similar kinetics
precipitated with anti-RTA antibody and analyzed by autoradiography (top) or immunoblot with anti-RTA antibody (bottom). (C) 293T cells were
transfected with reporter plasmids and plasmids containing RTA, TRAF6, IKKb, and IKKbDKD. Luciferase activity normalized against b-galactosidase
activity was shown. (D) Phosphorylation of GST fusion proteins, containing the C-terminal 127 amino acids of wild-type RTA, STS/A, or TTS/A variants,
by IKKb was analyzed similarly as in (A). (E) 293T transfection and luciferase reporter assays were carried out as in (C). (F) Whole cell lysates of 293T
transfected with plasmids containing wild-type RTA, STS/A, or TTS/A variants were analyzed by immunoblot (top) and used to normalize the basal
transcriptional activity of wild-type RTA, the STS/A and TTS/A variants (bottom). Data in (C), (E), and (F) represent the mean 6 SEM with indicated P
values (*, P,0.05; **, P,0.02) of at least three independent experiments.
doi:10.1371/journal.ppat.1001001.g005
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PLoS Pathogens | www.plospathogens.org 9 July 2010 | Volume 6 | Issue 7 | e1001001Figure 6. Generation and characterization of cHV68 BAC carrying the TTS/A mutation. (A) Diagram of the strategy to generate
recombinant cHV68. Briefly, wild-type RTA or the STS/A and TTS/A alleles were PCR amplified with overlapping PCR primers. Purified PCR products
were transfected into NIH3T3 cells, together with the BAC clone containing a transposon within the transactivation domain of RTA. Recombinant
viruses in the supernatant were used to infect NIH3T3 cells. Circular BAC DNA was purified and electroporated into DH10B cells. Chl, chloramphenicol;
Kan, kanamycin. (B and C) BACs containing cHV68 genome were analyzed by KpnI (B) or EcoRI (C) digestion, and resolved on 0.8% agarose gels
stained with ethidium bromide. The white arrows indicate the specific fragment shift caused by homologous recombination within the RTA locus. NR,
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2/2, and IKKb
2/2 MEFs, suggesting that the
MAVS-IKKb pathway functions on RTA to promote viral lytic
replication (Figure 7B and 7C). However, these replication defects
of recombinant cHV68 carrying the TTS/A mutation are much
more pronounced than the phenotypes of wild-type cHV68 in
MAVS
2/2 and IKKb
2/2 MEFs, implying that additional kinases
may influence RTA transcriptional activation via phosphorylation
of the TTS site. Taken together, we conclude that the TTS site of
RTA is likely phosphorylated by IKKb and is crucially important
for cHV68 lytic replication.
Discussion
Here we provide evidence that murine cHV68 hijacks the
antiviral MAVS-IKKb pathway to promote its lytic replication.
The MAVS adaptor is important for host defense against invading
pathogens, including various DNA and RNA viruses. For
example, mice lacking MAVS were severely compromised in
innate immune defense against VSV infection, leading to an
elevated peak viral load and prolonged acute viral infection [34].
The antiviral effects of MAVS have been observed against the
infection of a number of RNA and DNA pathogens [35,36,37]. To
our surprise, cHV68 viral load in the lungs of MAVS
2/2 mice
was significantly lower than that in the lungs of MAVS
+/+ mice at
10 d.p.i. The reduced viral load of cHV68 in MAVS
2/2 mice is
counter-intuitive to the presumed antiviral function of the MAVS
adaptor in promoting innate immune responses. Although type I
interferons in cHV68-infected mice were undetectable [38], mice
deficient in type I IFN receptor had higher viral loads and
succumbed to cHV68 infection [39]. We surmise that the effects of
MAVS deficiency on cHV68 acute infection is likely under-
estimated, providing that MAVS is critical for interferon
production in response to viral infection. Thus, the viral load of
cHV68 acute infection in MAVS
2/2 mice likely represents a
‘‘neutralized’’ phenotype, in which reduced cHV68 lytic replica-
tion is compensated by the lack of type I interferon inhibition.
Moreover, the observation that viral RTA mRNA levels correlates
tightly with the MAVS mRNA levels during early cHV68 acute
infection suggests that MAVS is necessary for cHV68 lytic
replication (Figure S2). Although we have not formally excluded
the contribution of host immune responses against cHV68
infection to the reduced viral load at 10 d.p.i. in MAVS
2/2
mice, our experiments with cHV68 replication ex vivo demonstrat-
ed critical roles of the MAVS-IKKb pathway in facilitating
cHV68 lytic infection.
During early stages of viral infection, cHV68 activated IKKb in
a MAVS-dependent manner, a signaling event that is likely
triggered by a variety of pathogens. The MAVS-dependent
activation was supported by elevated IKKb kinase activity and
accelerated IkBa degradation, signature signaling events down-
stream of the MAVS adaptor. Although the up-regulation of
IKKb kianse activity appears modest, cHV68 may direct IKKb
kinase activity to efficiently modify cellular and viral components
that are critical for cHV68 infection, such as RTA. Consequently,
cHV68 can harness activated IKKb without inducing NFkB
activation that may be resulted from massive IKKb activation.
Indeed, it was reported that cHV68 infection does not induce
NFkB activation during early infection [40], suggesting that
modest IKKb activation is beneficial for cHV68 infection and that
cHV68 may uncouple NFkB activation from IKKb activation.
Interestingly, cHV68 appears to block the interferon limb of the
MAVS-dependent innate immune pathway. In fact, we found that
cHV68 infection failed to induce the expression of IFN-b (Figure
S5A). Consistent with this observation, cHV68 RTA, similar to
KSHV RTA [30], is sufficient to reduce IRF3 protein (Figure
S5B), potentially abrogating the production of interferons that
otherwise would potently thwart cHV68 replication. Moreover,
ORF36 was reported to deregulate the phosphorylated form of
IRF3 and inhibit interferon production [41]. These observations
suggest that cHV68 selectively activates the MAVS-IKKb
pathway to promote viral lytic replication.
Within this report, we have identified one requisite role of the
MAVS-IKKb pathway in cHV68 lytic replication with MEFs
deficient in key components of this pathway. Phenotypically,
cHV68 displayed similar replication defects in MEFs deficient in
MAVS, IKKb, and IKKc, although the replication defects in
IKKb
2/2 and IKKc
2/2 MEFs were more pronounced than
those in MAVS
2/2 MEFs (Figure 1C, 2B, and 2C). This result
supports the corollary that IKKb, with the scaffold protein IKKc,
functions downstream of MAVS and likely integrates additional
signaling emanating from other innate immune pathways
including Toll-like receptors. It is worthy to point out that our
result does not exclude the antiviral activity of the IRF-IFN
pathway in cHV68 lytic replication, although deficiency of IRF3
and IRF7 or IFNAR did not appear to impact the initiation of
cHV68 lytic infection as assessed by plaque assays (Figure 2B). It is
possible that the IRF-IFN pathway may inhibit molecular events
other than the initiation of lytic replication and reduce viral yield
during cHV68 infection. Mechanistically, we identified cHV68
RTA, the master viral replication transactivator, as one of the
IKKb kinase substrates. Phosphorylation of RTA by IKKb
increases RTA transcriptional activity and consequently viral
mRNA production. Indeed, cHV68 had lower levels of various
mRNA transcripts that correlated with reduced lytic replication in
MAVS
2/2 MEFs (Figure 1 and 4). Conversely, exogenous
TRAF6 potentiated RTA transcriptional activity and substantially
increased the levels of viral mRNA transcripts (Figure 4F and 5C).
Additionally, exogenously reconstituted expression of MAVS and
IKKb restored RTA phosphorylation (Figure 5B) and restored
cHV68 lytic replication (Figure 1 and 2). Moreover, lytic
replication of recombinant cHV68 viruses carrying mutations
within the IKKb phosphorylation sites was greatly impaired,
displaying phenotypes that are more pronounced than those of
wild-type cHV68 in MEFs deficient in components of the MAVS-
IKKb pathway. Conceivably, other kinases and signaling
pathways may converge to modulate RTA transcriptional
activation via phosphorylation within these identified IKKb sites.
For example, virus-encoded kinases, such as the functionally
conserved ORF36, may amplify the phosphorylation cascade that
is initiated by the MAVS-IKKb pathway [42]. Most importantly,
RTA auto-activates its own promoter and increases RTA protein
that, in turn, up-regulates the expression of numerous immediate
early and early genes during cHV68 infection. Thus, the 50–80%
reduction in RTA transcriptional activity of the STS/A and TTS/
A variants (Figure 5F) likely translates into, through the
aforementioned amplification cascades, the viral yields that are
less than 0.1% of the recombinant cHV68.NR (Figure 7B).
Finally, it is noteworthy that deficiency in MAVS and IKKb and
RTA-null rescued. (D) 293T cells were transfected with cHV68 M3 reporter plasmid and BAC.NR or BAC.TTS/A. At 28 h post-transfection, luciferase
activity and b-galactosidase activity were determined and M3 transcriptional activation by RTA was shown. (E) Transfection of 293T cells with the
BAC.TTS/A DNA and a plasmid containing TRAF6, and qRT-PCR were carried out as in Figure 4F.
doi:10.1371/journal.ppat.1001001.g006
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PLoS Pathogens | www.plospathogens.org 11 July 2010 | Volume 6 | Issue 7 | e1001001Figure 7. Impaired lytic replication of recombinant cHV68 carrying the TTS/A mutation. (A) Wild-type MEFs were infected with equal
number of genomes, measured by qRT-PCR, of recombinant cHV68.NR (MOI=0.1) or cHV68.TTS/A. At 30 h post-infection, the RTA mRNA levels were
determined by reverse transcription and qRT-PCR. (B) Wild-type, MAVS
2/2, and IKKb
2/2 MEFs were infected with recombinant cHV68.NR (left) and
cHV68.TTS/A (right) (MOI=0.01) and the multi-step growth curves were determined by a plaque assay. Data represent three independent
experiments. (C) The lytic replication of recombinant cHV68.NR and cHV68.TTS/A was examined similarly as in (B) with an MOI of 0.1 (cHV68.NR).
doi:10.1371/journal.ppat.1001001.g007
Hijacking an Innate Immune Pathway for Viral Replication
PLoS Pathogens | www.plospathogens.org 12 July 2010 | Volume 6 | Issue 7 | e1001001mutations within RTA exhibited distinct phenotypes (such as peak
viral titers of multi-step growth curves), in addition to the shared
reduction of cHV68 lytic replication. These differing effects on
cHV68 infection are likely due to their unique hierarchical
position within the MAVS-IKKb-RTA signaling axis. In essence,
these experiments identified novel phosphorylation sites within
RTA that couples cHV68 lytic replication to the antiviral IKKb
kinase. These findings collectively demonstrate that the MAVS-
dependent IKKb kinase activity is critical for RTA transcriptional
activation and cHV68 lytic replication. Interestingly, Gwack et al.
reported that phosphorylation of the internal serine/threonine-
rich region of KSHV and cHV68 RTA inhibited RTA
transcriptional activity and suppressed viral lytic replication [43].
Together with our findings, these results indicate that site-specific
phosphorylation determines the transcriptional activity, and likely
the promoter-specificity, of gamma-herpesvirus RTA.
Although it is well accepted that the NFkB pathway is crucial
for gamma-herpesvirus latent infection [44], the roles of this
pathway in gamma-herpesvirus lytic replication appear to be
inconsistent. Particularly, Krug et al. reported that the recombi-
nant cHV68 expressing the IkBa super suppressor replicated
indistinguishably compared to wild type cHV68 [31]. Thus, the
authors concluded that the NFkB pathway is dispensable for
cHV68 lytic replication. By contrast, it was shown that RelA, the
p65 subunit of an NFkB transcription dimer, inhibits cHV68 lytic
replication through suppressing RTA transcription activity in
293T cells [45]. Finally, our current report indicates that the
MAVS-IKKb pathway is necessary for efficient cHV68 lytic
replication. However, the seemingly paradox can be explained by
the differential effects of three distinct components of the NFkB
pathway on cHV68 lytic replication. Although the IkBa super
suppressor is commonly employed to inhibit the activation of the
NFkB transcription factors, it is important to note that no
significant NFkB activation was observed during early cHV68
infection (within the first 6 hours post-infection) [40], temporal
phase in which the critical roles of IKKb was indentified by our
genetic and biochemical experiments. Conceivably, the unpho-
sphorylatable IkBa super suppressor may not impact IKKb kinase
activity. By contrast, we have focused on the IKKb kinase and our
study indicated that the ability of IKKb to promote viral lytic
replication largely stems from IKKb kinase activity to phosphor-
ylate RTA and increase RTA transcriptional activation. Appar-
ently, neither IkBa, nor RelA can do so in replace of IKKb
function. On the other hand, although RelA was shown to
suppress cHV68 lytic replication [45], the lack of NFkB activation
during early cHV68 infection implies that cHV68 uncouples
NFkB activation from IKKb activation, which are otherwise
tightly correlated. As such, cHV68 infection may selectively
activate the IKKb kinase, while sparing the inhibition by
preventing NFkB activation. Therefore, a scenario that potentially
accommodates all three reports is that nuclear activated RelA is
necessary to inhibit cHV68 lytic replication and cHV68 is capable
of preventing RelA activation in an IkBa-independent manner.
Crucial to this hypothesis is the mechanisms that cHV68 has
evolved to thwart NFkB activation and future experiments are
necessary to address this possibility.
It was previously reported that cHV68 was impaired for latency
establishment and reactivation in MyD88-deficient mice, although
the lytic replication of cHV68 appeared to be normal in these
mice [26]. Moreover, agonists specific for TLR7/8, which activate
downstream signaling events through MyD88, induced KSHV
lytic gene expression and reactivated KSHV replication from
latently-infected B cells [25]. The specific roles of MAVS in lytic
replication and MyD88 in latent infection are consistent with their
distinct functions in innate immune responses of epithelial cells
and immune cells, respectively. Given that MyD88 also activates
the IKKa/b kinase complex, it is possible that IKKb-dependent
activation of RTA may contribute to cHV68 and KSHV latent
infection as well. Finally, reduced lytic replication of human
KSHV and cytomegalovirus has been observed under experimen-
tal conditions in which IKKb was inhibited by Bay11, implying
that human KSHV and cytomegalovirus have evolved similar
molecular mechanisms to facilitate lytic replication [46,47,48].
Taken together, the mechanism whereby an antiviral innate
immune signaling pathway is exploited to promote viral lytic
replication may be applied to other herpesviruses and viral
reactivation from latency. This study thus has uncovered an
intricate interplay between the viral replication transactivator,
RTA, and the MAVS-IKKb pathway. To our best knowledge, this
is the first example that illustrates how a virus hijacks an antiviral
signaling pathway, downstream of cytosolic sensors, to initiate its
lytic replication. Perhaps, co-evolution between the persistent
herpesviruses and their hosts has selected viruses that exploited the
inevitable innate immune activation by viral infection. Although
our current study delineates the key signaling events downstream
of MAVS and IKKb, it remains unknown what viral components
and cellular factors activate the MAVS-IKKb pathway and
whether these mechanisms are shared by the oncogenic KSHV
and EBV to promote lytic replication or reactivation.
Materials and Methods
Plasmids
For protein expression in mammalian cells, all genes were
cloned into pcDNA5/FRT/TO (Invitrogen) unless specified. For
protein expression and purification in E.coli, the internal region
(RTA-M, aa 335–466) and C-terminal transactivation domain
(RTA-C, aa 457–583) of RTA were cloned into pGEX-4T-1
(Promega) with BamHI and XhoI sites.
Cells and Viruses
NIH3T3 cells, HEK293T (293T) cells and mouse embryonic
fibroblasts (MEFs) were maintained in DMEM (Mediatech) with
8% newborn calf serum (NCS) or fetal bovine serum (FBS),
respectively. MAVS
+/+, MAVS
2/2, IKKb
2/2, IKKc
2/2 and
TRAF6
2/2 MEFs were described previously [4,34]. IKKa
2/2
MEFs were kindly provided by Dr. Amyn A. Habib (Neurology,
UT Southwestern). IFNAR
+/+ and IFNAR
2/2 MEFs were kindly
provided by Dr. Michael Gale (Immunology, University of
Washington). IRF3
+/+IRF7
+/+ and IRF3
2/2IRF7
2/2 MEFs were
kindly provided by Dr. Jae Jung (Microbiology, University of
Southern California). cHV68 K3/GFP was kindly provided by
Dr. Philip Stevenson (Cambridge University, UK). Wild-type
cHV68 and cHV68 K3/GFP were amplified in NIH3T3 cells,
and VSV-GFP virus was amplified in BHK-21 cells. Viral titer was
determined by a plaque assay with NIH3T3 cells.
Mice and Infections
All animal experiments were performed in accordance to NIH
guidelines, the Animal Welfare Act, and US federal law. The
experimental protocol (entitled: Innate immune pathways in
cHV68 infection) were approved by the Institutional Animal
Care and Use Committee (IACUC). All animals were housed in a
centralized research animal facility that is accredited by the
Association of Assessment and Accreditation of Laboratory
Animal Care International, and that is fully staffed with trained
husbandry, technical, and veterinary personnel.
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+/+), heterozygous (MAVS
+/2), and knockout
(MAVS
2/2) mice were described previously [34]. Gender-
matched, 6- to 8-week old littermate mice were intranasally (i.n.)
inoculated with 40 plaque-forming unit (PFU) wild-type cHV68.
To assess MAVS expression in the lung and spleen, BL/6 mice
were intranasally infected with 1610
5 PFU cHV68. The lungs and
spleens were harvested and homogenized in DMEM.
Plaque Assay
Viral titer of mice tissues or cell lysates was assessed by a plaque
assay on NIH3T3 monolayers. After three rounds of freezing and
thawing, 10-fold serially-diluted virus supernatants were added
onto NIH3T3 cells and incubated for 2 hours at 37uC. Then,
DMEM containing 2% NCS and 0.75% methylcellulose (Sigma)
was added after removing the supernatant. Plaques were counted
at day 6 post-infection. The detection limit for this assay is 5 PFU.
To assess the infectivity of cHV68 on various MEFs, a similar
plaque assay was carried out with the initial cell density of 5000
cells/cm
2. In Bay11-7082 treatment assay, 0.5mMo r1 mM Bay11-
7082 was added at 0.5 h before infection or 7 h post-infection.
Supernatant was removed after 30 min incubation at 37uC, and
cells were washed with medium and incubated for plaque
formation.
Protein Expression and Purification
Glutathione-S-transferase (GST) and GST fusion proteins
containing the internal region and the transactivation domain of
RTA were expressed with IPTG induction and purified with
glutathione-sepharose as previously described [33]. Eluted proteins
were re-suspended in 25% glycerol and stored at 220uC for kinase
assays. To purify IKKb and IKKbDKD, 293T cells were
transfected with pcDNA3 containing Flag-IKKb and Flag-
IKKbDKD. At 48 h post-transfection, cells were lysed with kinase
purification buffer (150 mM NaCl, 20 mM Tris.HCl pH7.4, 10%
Glycerol, 0.5% Triton X-100, 0.5 mM DTT) and subject to one-
step affinity purification with anti-Flag M2-conjugated agarose
(Sigma). Proteins were eluted with 0.2 mg/ml Flag peptide in
kinase buffer (50 mM KCl, 2 mM MgCl2, 2 mM MnCl2,1m M
DTT, 10 mM NaF, 25 mM HEPES, pH7.5) and stored in 25%
glycerol at 280uC.
Antibodies
Commercial antibodies used in this study include: anti-Flag
(Sigma), anti-GFP (Covance), anti-IKKb (H4), anti-IkBa (C20)
(Santa Cruz Biotech.), anti-actin (Abcam.). To generate antibody
to cHV68 RTA, the mixture of GST fusion proteins containing
the RTA-M and RTA-C was used to immunize a rabbit and
polyclonal antibodies were tested for the specificity with pre-
immune serum as control.
In Vitro Kinase Assay
Endogenous IKKb or exogenously expressed IKKb and
IKKbDKD were used for in vitro kinase assays. The kinase
reaction includes 0.5 mg GST or GST fusion proteins, 100 mCi
[
32P]cATP, and approximately 250 ng kinase in 20 ml of kinase
buffer. Reaction was incubated at room temperature for 25 min
and denatured proteins were analyzed by SDS-PAGE and
autoradiography.
Reverse Transcription (RT)-PCR and Quantitative Real-
Time PCR (qRT-PCR) Analysis
To determine the relative levels of viral transcripts, total RNA
was extracted from MEFs or mice tissues using TRIzol reagent
(Invitrogen). To remove genomic DNA, total RNA was treated
with RNase-free DNase I (New England Biolab) at 37uC for
1 hour. After heat inactivation, total RNA was re-purified with
TRIzol reagent. cDNA was prepared with 1.5 mg total RNA and
reverse transcriptase (Invitrogen). RNA was then removed by
incubation with RNase H (Epicentre). Abundance of viral
transcripts was assessed by qRT-PCR. Mouse b-actin was used
as an internal control. Primers used in this study were summarized
in Table S1.
Limiting-Dilution Ex Vivo Reactivation Analyses
Bulk splenocytes were re-suspended in DMEM, and plated onto
primary MEF monolayers in 96-well plates in 2-fold serial
dilutions (from 10
5 to 48 cells/well) as previously described [49].
Twelve wells were plated every dilution. Reactivation percentage
was scored for cytopathic effects (CPE) positive wells on day 6. In
order to measure preformed infectious virus, disrupted cells were
plated onto primary MEF monolayers. This procedure destroys
over 99% of the cells, but has minimal effect on preformed
infectious virus, thus allowing distinction between reactivation
from latency and persistent infection.
Limiting-Dilution Nested PCR (LDPCR) Detection of
cHV68 Genome-positive Cells
The frequency of splenocytes harboring wild-type cHV68
genome was assessed by a single-copy-sensitive nested PCR
analysis of serial dilutions of splenocytes as previously described
[49]. Briefly, mice spleens were homogenized and re-suspended in
isotonic buffer and subjected to 3-fold serial dilutions (from 10
4 to
41 cells/well) in a background of uninfected RAW 264.7 cells, with
a total of 10
4 cells per well. Twelve replicates were plated for each
cell dilution. After being plated, cells were subjected to lysis by
proteinase K at 56uC for 8 hours. After inactivating the enzyme
for 30 minutes at 85uC, samples were subjected to nested PCR
using primers specific for cHV68 ORF72. Positive controls of 10,
1, and 0.1 copies of viral DNA and negative controls of uninfected
RAW 264.7 cells alone were included on each plate. Reaction
products were separated using 2.5% UltraPure agarose (Invitro-
gen) gels and visualized by ethidium bromide staining.
Statistical Analyses
Reactivation and LDPCR results were analyzed using Graph-
Pad Prism software (GraphPad Software, San Diego, CA). The
frequencies of genome-positive cells were statistically analyzed
using the paired Student’s t-test. The frequencies of viral genome-
positive cells were determined from a nonlinear regression analysis
of sigmoidal dose-response best-fit curve data. Based on a Poisson
distribution, the frequency at which at least one event is present in
a given population occurs at the point at which the regression
analysis line intersects 63.2%. Pooled data of at least three
independent experiments were used to calculate P values with the
two-tailed, unpaired Student’s t-test.
Luciferase Reporter Assay
293T cells (2610
5 cells/well) were seeded in 24-well plates
16 hours before transfection. A total of 377 ng of plasmid DNA
per well was co-transfected by the calcium phosphate method
(Clontech). The plasmid cocktail includes 75 ng of luciferase
plasmid (RTAp_luc, ORF57p_Luc or M3p_luc), 200 ng of
pCMV-b-galactosidase plasmid, 2 ng of pcDNA5_RTA and
100 ng of pcDNA5 containing TRAF6, IKKb or IKKbDKD.
At 21 hours post-transfection, whole cell lysates were used to
measure the firefly luciferase activity and b-galactosidase activity.
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The bacterial artificial chromosome (BAC) system was used to
generate recombinant cHV68 similarly to what was described
previously [33]. Briefly, wild-type RTA or the STS/A and TTS/A
alleles were PCR amplified with overlapping PCR primers. Purified
PCR products, along with the BAC clone 5.15 [32] containing a
transposon within the transactivation domain of RTA (between
nucleotide 69269 and 69270, according to accession number
U97553), were transfected into NIH3T3 cells with Lipofectamine
2000 (Invitrogen). Virus in the supernatant was further amplified
with NIH3T3 cells. To isolate circular BAC DNA, NIH3T3 cells
were infected with recombinant cHV68 and DNA was extracted
according to Hirt’s protocol [50] and electroporated into Electro-
MAX DH10B cells (Invitrogen). BAC DNA containing cHV68
genome was digested with EcoRI and KpnI to rule out chromosome
rearrangement. Meanwhile, the RTA alleles were amplified by
PCR and sequenced to confirm desired mutations. Selected clones
were transfected into NIH3T3 cells and recombinant cHV68 was
amplified for subsequent experiments.
NCBI Entrez Gene ID List
RIG-I, 230073; MDA-5, 71586; MAVS, 228607; TBK-1,
56480; IKKe, 56489; IRF3, 54131; IRF7, 54123; c-Jun, 16476;
ATF-2, 11909; IFNb, 15977; IFNAR, 15975; TRAF3, 22031;
TRAF6, 22034; IKKc, 16151; IKKa, 12675; IKKb, 16150;
IkBa, 18035; NFkB1, 18033; RelA, 19697; MyD88, 35956;
TLR7, 170743; TLR8, 170744.
Supporting Information
Figure S1 Normal cHV68 Latent Infection in MAVS
2/2 Mice.
Six- to 8-week old mice were intranasally infected with 40 PFU
wild-type cHV68. Limiting dilution assays were carried out with
splenocytes of MAVS
+/+ mice (filled square and circle) or
MAVS
2/2 mice (open square and circle). Viral genome frequency
(A), preformed infection and reactivation at day 16 (B) and day 45
(C) post-infection were measured as described in Materials and
Methods. The data were compiled from two independent
experiments with four mice per group per experiment, and are
presented as the mean 6 standard error of the mean (SEM).
Found at: doi:10.1371/journal.ppat.1001001.s001 (0.28 MB TIF)
Figure S2 Correlation Between cHV68 RTA mRNA Levels
and MAVS mRNA Levels. (A and B) BL/6 mice were intranasally
infected with 1610
5 PFU cHV68, and the mRNA levels of MAVS
(A) and viral RTA (B) in the lungs and spleens were determined by
reverse transcription and qRT-PCR using comparative CT
method. (C) Correlation between the viral RTA mRNA levels
(B) and the MAVS mRNA levels (A) in the lungs (at 2.5 [filled
circle] and 5 [open square] d.p.i.) (left) and spleens (at 5 d.p.i.
[filled triangle]) (right). Dashed lines represent the linear regression
between viral RTA mRNA levels and MAVS mRNA levels.
Found at: doi:10.1371/journal.ppat.1001001.s002 (0.23 MB TIF)
Figure S3 Delayed Lytic Replication of cHV68 in MAVS
2/2
MEFs. MAVS
+/+ (filled triangle) and MAVS
2/2 (open triangle)
MEFs were infected with cHV68 K3/GFP virus at the multiplicity
of infection (MOI) of 0.1. (A) cHV68 infected cells were
photographed at day 3 and day 5 post-infection (d.p.i.). (B)
Multi-step growth curve of cHV68 was determined by a plaque
assay. Results represent the mean 6 SEM of three independent
experiments.
Found at: doi:10.1371/journal.ppat.1001001.s003 (0.57 MB TIF)
Figure S4 Reduced Initiation of cHV68 Lytic Replication in
MAVS
2/2 MEFs. MAVS
+/+ (filled circle) and MAVS
2/2 (open
circle) MEFs were infected with cHV68 K3/GFP. (A) Methylcel-
lulosewasadded toblockviraltransmissionthroughthesupernatant
at time pointsas indicated. PlaquesformedbycHV68 were counted
at day 6 post-infection. The results are expressed as the mean 6
SEM of three independent samples. (B to D) Methylcellulose was
added at 2 hours post-infection. (B) Plaques were counted after
infection of indicated dose of cHV68. The results are expressed as
the mean 6 SEM of three independent samples. (C) Plaques were
photographed by fluorescent microscopy. Results represent four
independent wells of both cell lines. (D) Plaque dimensions were
measured on MAVS
+/+ (n=86) and MAVS
2/2 MEFs (n=81).
Each solid or open circle represents a plaque.
Found at: doi:10.1371/journal.ppat.1001001.s004 (1.12 MB TIF)
Figure S5 cHV68 does not Induce IFNb Gene Expression in
MEFs. (A) MAVS
+/+ and MAVS
2/2 MEFs were infected with
cHV68 (MOI=5) or Sendai virus (150 HA Units) separately.
IFNb mRNA levels were determined by reverse transcription and
quantitative real-time PCR. (B) 293T cells were transfected with
plasmids carrying IRF3-GFP and cHV68 RTA. IRF3 protein
levels after 48 hours were monitored by GFP fluorescence
microscopy.
Found at: doi:10.1371/journal.ppat.1001001.s005 (0.67 MB TIF)
Figure S6 IKKb, but not IKKa, Phosphorylates GST-RTA-C.
GST, GST-RTA-M, and GST-RTA-C were incubated with
[
32P]cATP and IKKa or IKKb, and analyzed by coomassie
staining or autoradiography. IKKa and IKKb were analyzed by
immunoblot with anti-Flag antibody.
Found at: doi:10.1371/journal.ppat.1001001.s006 (0.30 MB TIF)
Figure S7 TRAF6, IKKb or IKKbDKD does not Activate the
Promoters of cHV68 Lytic Genes. (A) 293T cells were transfected
with reporter plasmids and 100 ng plasmids containing TRAF6,
IKKb or IKKbDKD. Luciferase activity was normalized against
b-galactosidase activity. Data represent the mean 6 SEM of at
least five independent experiments. (B and C) 293T cells were
transfected with reporter plasmids, RTA (2 ng) and IKKb
(100 ng) or IKKbDKD (200, 500 and 1000 ng). (B) Whole cell
lysates (WCLs) were analyzed by immunoblot with anti-Flag
antibody for IKKb and IKKbDKD expression. The relative molar
ratio between IKKb and IKKbDKD was calculated by normal-
izing immunoblot intensity to the b-galactosidase activity (b-Gal)
and their molecular weights. (C) Luciferase activity normalized
against b-galactosidase activity was shown. Vec, empty vector.
Found at: doi:10.1371/journal.ppat.1001001.s007 (0.38 MB TIF)
Figure S8 Identification of IKKb Phosphorylation Sites within
cHV68 RTA. GST and a panel of GST-RTA fusion proteins with
serial truncations (top) or site-specific mutations (bottom) were
analyzed by in vitro kinase assays with IKKb. Relative intensity of
phosphorylated GST-RTA fusion protein was quantified in
reference to GST-RTA-C. ND, not done.
Found at: doi:10.1371/journal.ppat.1001001.s008 (0.18 MB TIF)
Table S1 Primer List. All primers used in this study were
synthesized by Invitrogen or Sigma. PCR primers were designed
by MacVector 9.0 (Accelrys Inc.), and qRT-PCR (quantitative
Real-Time PCR) primers were designed by Primer Express 3.0
(Applied Biosystems).
Found at: doi:10.1371/journal.ppat.1001001.s009 (0.23 MB TIF)
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